2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.11: Clinical Outcomes of Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: Experience from an Oncology Center in Bogotá, Colombia

PP01.11: Clinical Outcomes of Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: Experience from an Oncology Center in Bogotá, Colombia

Back to course

Pdf Summary

The retrospective study conducted by Bejarano-Ramirez et al. evaluated the clinical outcomes of using Osimertinib in treating patients with non-small cell lung cancer (NSCLC) and documented EGFR mutations in Bogotá, Colombia. The study focused on a cohort of 77 patients, predominantly female, with an average age of 65, where 49% were diagnosed at TNM stage IV. The analysis revealed that exon 19 was the most common mutation site, present in 49% of cases.<br /><br />Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), was given to 46.7% of the patients, with 69% receiving it as the first-line treatment. The study's primary aim was to compare the efficacy of Osimertinib with other pharmacological therapies within the Latin American population. Data indicated that 70% of the patients are still alive, with a narrow distribution between those treated with Osimertinib and other therapies. The median overall survival (OS) was 23.3 months for those on Osimertinib versus 25.5 months for other therapies, although this difference was not statistically significant.<br /><br />An interesting finding emerged for patients who were administered Osimertinib as second-line treatment, experiencing an OSm of 34 months, in contrast to just 20.5 months for those treated with it as a first-line option. This suggests potential benefits of using Osimertinib as a second-line treatment approach.<br /><br />The study concluded no significant overall survival differences were observed between Osimertinib and alternative therapies in first-line treatment. However, improved outcomes in second-line therapy with Osimertinib warrant further investigation, underscoring the need for larger, randomized studies to substantiate these findings.

Asset Subtitle

Andres Felipe Bejarano-Ramirez

Keywords

Osimertinib

non-small cell lung cancer

NSCLC

EGFR mutations

Bogotá

exon 19

third-generation TKI

first-line treatment

second-line treatment

overall survival